Payment overview · 2025
General Payments
$460.39
8 reported records · 4 companies
Healthcare provider profile · identity verified
Ashley Michelle Scott, DO
Allopathic & Osteopathic Physicians|Family Medicine · COWETA, OK · NPI 1205325941
Verified facts
What the public records show
CMS Open Payments records show Ashley Michelle Scott, DO received $460.39 in general payments during 2025 across 8 reported records.
Lilly USA, LLC accounted for 80.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Mounjaro.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 565 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 696 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 380 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $369.52 | 80.3% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $60.90 | 13.2% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.34 | 3.5% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $13.63 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $460.39 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $250.00 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $119.52 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $60.90 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $60.90 | 3 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $41.79 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.11 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $13.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 29 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 55 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
565 | 80 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
696 | 104 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
29 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
380 | 65 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1250 | 209 |
| Lisinopril | Lisinopril | 940 | 149 |
| Amlodipine Besylate | Amlodipine Besylate | 740 | 122 |
| Losartan Potassium | Losartan Potassium | 731 | 131 |
| Ozempic | Semaglutide | 696 | 104 |
| Gabapentin | Gabapentin | 678 | 107 |
| Omeprazole | Omeprazole | 664 | 112 |
| Metformin Hcl | Metformin Hcl | 631 | 95 |
| Synthroid | Levothyroxine Sodium | 616 | 103 |
| Hydrochlorothiazide | Hydrochlorothiazide | 611 | 100 |
| Jardiance | Empagliflozin | 565 | 80 |
| Fluticasone Propionate | Fluticasone Propionate | 519 | 116 |
| Metoprolol Succinate | Metoprolol Succinate | 498 | 86 |
| Montelukast Sodium | Montelukast Sodium | 458 | 63 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 428 | 66 |
| Furosemide | Furosemide | 402 | 68 |
| Eliquis | Apixaban | 380 | 65 |
| Potassium Chloride | Potassium Chloride | 363 | 75 |
| Pantoprazole Sodium | Pantoprazole Sodium | 347 | 53 |
| Carvedilol | Carvedilol | 343 | 53 |
| Duloxetine Hcl | Duloxetine Hcl | 297 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 271 | 47 |
| Meloxicam | Meloxicam | 265 | 51 |
| Alogliptin | Alogliptin Benzoate | 258 | 35 |
| Trazodone Hcl | Trazodone Hcl | 256 | 41 |
| Diclofenac Sodium | Diclofenac Sodium | 236 | 55 |
| Tizanidine Hcl | Tizanidine Hcl | 226 | 31 |
| Fenofibrate | Fenofibrate Nanocrystallized | 208 | 30 |
| Droplet Pen Needle | Pen Needle, Diabetic | 199 | 30 |
| Spiriva Respimat | Tiotropium Bromide | 199 | 28 |
| Atenolol | Atenolol | 195 | 31 |
| Simvastatin | Simvastatin | 191 | 41 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 185 | 28 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 184 | 34 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 182 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 180 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 173 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 170 | 30 |
| Famotidine | Famotidine | 162 | 23 |
| Novolog Flexpen | Insulin Aspart | 161 | 36 |
| Pioglitazone Hcl | Pioglitazone Hcl | 161 | 27 |
| Tresiba Flextouch U-100 | Insulin Degludec | 159 | 33 |
| Ezetimibe | Ezetimibe | 155 | 24 |
| Oxybutynin Chloride | Oxybutynin Chloride | 153 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 148 | 52 |
| Allopurinol | Allopurinol | 146 | 23 |
| Sertraline Hcl | Sertraline Hcl | 140 | 29 |
| Alendronate Sodium | Alendronate Sodium | 137 | 32 |
| Ibuprofen | Ibuprofen | 135 | 25 |
| Finasteride | Finasteride | 130 | 21 |
| Buspirone Hcl | Buspirone Hcl | 128 | 22 |
| Glipizide Er | Glipizide | 124 | 21 |
| Baclofen | Baclofen | 116 | 21 |
| Doxazosin Mesylate | Doxazosin Mesylate | 116 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 104 | 17 |
| Celecoxib | Celecoxib | 104 | 20 |
| Topiramate | Topiramate | 103 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 101 | 16 |
| Propranolol Hcl | Propranolol Hcl | 100 | 15 |
| Spironolactone | Spironolactone | 100 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 97 | 19 |
| Bupropion Xl | Bupropion Hcl | 93 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 91 | 15 |
| Humalog Kwikpen U-100 | Insulin Lispro | 88 | 12 |
| Torsemide | Torsemide | 88 | 21 |
| Clonidine Hcl | Clonidine Hcl | 84 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 82 | suppressed |
| Pregabalin | Pregabalin | 80 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 79 | suppressed |
| Xarelto | Rivaroxaban | 79 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 77 | 14 |
| Tresiba Flextouch U-200 | Insulin Degludec | 72 | 11 |
| Levemir Flexpen | Insulin Detemir | 70 | 29 |
| Bupropion Hcl Sr | Bupropion Hcl | 69 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 69 | suppressed |
| Aripiprazole | Aripiprazole | 67 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 67 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 67 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 64 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 64 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 62 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 61 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 61 | suppressed |
| Entresto | Sacubitril/Valsartan | 59 | suppressed |
| Ondansetron Odt | Ondansetron | 59 | 19 |
| Naproxen | Naproxen | 58 | 12 |
| Mirtazapine | Mirtazapine | 56 | suppressed |
| Mounjaro | Tirzepatide | 55 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 54 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 51 | 13 |
| Lactulose | Lactulose | 50 | 21 |
| Nifedipine Er | Nifedipine | 50 | suppressed |
| Nitroglycerin | Nitroglycerin | 50 | 15 |
| Valacyclovir | Valacyclovir Hcl | 50 | suppressed |
| Memantine Hcl | Memantine Hcl | 48 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 46 | 12 |
| Premarin | Estrogens, Conjugated | 44 | 12 |
| Methotrexate | Methotrexate Sodium | 41 | suppressed |
| Linzess | Linaclotide | 38 | suppressed |
| Lactated Ringers | Ringer's Solution,lactated | 35 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 34 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 14 |
| Lamotrigine | Lamotrigine | 32 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 31 | 21 |
| Midodrine Hcl | Midodrine Hcl | 30 | suppressed |
| Trulicity | Dulaglutide | 30 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 29 | 27 |
| Sucralfate | Sucralfate | 29 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Lidocaine | Lidocaine | 26 | suppressed |
| Prednisone | Prednisone | 26 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 26 | 11 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 25 | suppressed |
| Invokana | Canagliflozin | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Verapamil Er | Verapamil Hcl | 24 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 23 | suppressed |
| Calcium Acetate | Calcium Acetate | 22 | suppressed |
| Repatha Sureclick | Evolocumab | 22 | suppressed |
| Temazepam | Temazepam | 21 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Methimazole | Methimazole | 19 | suppressed |
| Brilinta | Ticagrelor | 17 | suppressed |
| Cephalexin | Cephalexin | 17 | 12 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Alprazolam | Alprazolam | 16 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 16 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Mupirocin | Mupirocin | 15 | 12 |
| Terbinafine Hcl | Terbinafine Hcl | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 12 |
| Anastrozole | Anastrozole | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Sulfasalazine | Sulfasalazine | 14 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Enbrel Sureclick | Etanercept | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 13 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Letrozole | Letrozole | 13 | suppressed |
| Movantik | Naloxegol Oxalate | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 12 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 12 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 12 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Glyburide | Glyburide | 11 | suppressed |
| Indomethacin | Indomethacin | 11 | suppressed |
| Jantoven | Warfarin Sodium | 11 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $460.39 · 8 records | Lilly USA, LLC | ABRYSVO, COMIRNATY, Dexcom G6 Transmitter, MOUNJARO, PENBRAYA, PREVNAR 20, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error